Cancer treatment may be entering a new era as researchers identify how malignant cells use molecular condensates—dense protein clusters within cells—to drive tumor growth and drug resistance. These condensates function like cellular factories, concentrating cancer-promoting proteins in specific locations to amplify their harmful effects. The discovery represents a fundamental shift from targeting individual proteins to disrupting entire molecular neighborhoods that fuel malignancy. Scientists have identified several classes of compounds capable of dissolving these oncogenic condensates or preventing their formation. Small molecule inhibitors can disrupt the weak molecular interactions that hold condensates together, while other drugs target the specific proteins that seed condensate formation. Early laboratory studies show these approaches can restore normal cell function and sensitize resistant tumors to conventional therapies. The condensate-targeting strategy addresses a critical limitation in current cancer treatment: the tendency of tumors to develop resistance by reorganizing their internal machinery. By disrupting these organizational hubs, the approach potentially prevents cancer cells from coordinating their survival mechanisms. However, significant challenges remain before clinical application. Normal cells also rely on condensates for essential functions, raising concerns about therapeutic selectivity. The field lacks standardized methods for measuring condensate formation in patients, complicating treatment monitoring. Additionally, most research has focused on laboratory models, with limited understanding of how condensate dynamics vary across different cancer types and patient populations. While promising, this approach requires extensive validation to determine whether disrupting cellular organization can translate into meaningful patient outcomes without unacceptable toxicity.